Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Fatigue - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 33 | Code: MRS - 18499


Global Markets Directs, Fatigue Pipeline Review, H1 2015, provides an overview of the Fatigues therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fatigue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatigue and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Fatigue
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Fatigue and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Fatigue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Fatigue pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Fatigue
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Fatigue pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2
List of Tables 3
List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4
Fatigue Overview 5
Therapeutics Development 6
Pipeline Products for Fatigue - Overview 6
Pipeline Products for Fatigue - Comparative Analysis 7
Fatigue - Therapeutics under Development by Companies 8
Fatigue - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Fatigue - Products under Development by Companies 12
Fatigue - Companies Involved in Therapeutics Development 13
Biovista Inc. 13
Dimerix Bioscience Pty Ltd 14
Hemispherx Biopharma, Inc. 15
Merz Pharmaceuticals GmbH 16
MultiCell Technologies, Inc. 17
PharmaLundensis AB 18
Teva Pharmaceutical Industries Limited 19
Fatigue - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Fatigue - Dormant Projects 30
Fatigue - Product Development Milestones 31
Featured News & Press Releases 31
Jun 14, 2010: MultiCell Retains CDSS To Manage MCT-125 Phase IIb Clinical Trial For PMSF In UK 31

Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables

Number of Products under Development for Fatigue, H1 2015 6
Number of Products under Development for Fatigue - Comparative Analysis, H1 2015 7
Number of Products under Development by Companies, H1 2015 8
Comparative Analysis by Late Stage Development, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Fatigue - Pipeline by Biovista Inc., H1 2015 13
Fatigue - Pipeline by Dimerix Bioscience Pty Ltd, H1 2015 14
Fatigue - Pipeline by Hemispherx Biopharma, Inc., H1 2015 15
Fatigue - Pipeline by Merz Pharmaceuticals GmbH, H1 2015 16
Fatigue - Pipeline by MultiCell Technologies, Inc., H1 2015 17
Fatigue - Pipeline by PharmaLundensis AB, H1 2015 18
Fatigue - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Assessment by Combination Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Fatigue - Dormant Projects, H1 2015 30

List of Figures
 

Number of Products under Development for Fatigue, H1 2015 6
Number of Products under Development for Fatigue - Comparative Analysis, H1 2015 7
Number of Products under Development by Companies, H1 2015 8
Comparative Analysis by Clinical Stage Development, H1 2015 10
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 22
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Top 10 Routes of Administration, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing